Abstract:The use of epigenetic bromodomain inhibitors as anticancer therapeutics has transitioned from targeting bromodomain extraterminal domain (BET) proteins into targeting non-BET bromodomains. The two most relevant non-BET bromodomain oncology targets are cyclic AMP response element-binding protein (CBP) and E1A binding protein P300 (EP300). To explore the growing CBP/EP300 interest, we developed a highly efficient two-step synthetic route for dimethylisoxazole-attached imidazo[1,2-a]pyridine scaffold-containing inhibitors. Our efficient two-step reactions enabled high-throughput synthesis of compounds designed by molecular modeling, which together with structure–activity relationship (SAR) studies facilitated an overarching understanding of selective targeting of CBP/EP300 over non-BET bromodomains. This led to the identification of a new potent and selective CBP/EP300 bromodomain inhibitor, UMB298 (compound 23, CBP IC50 72 nM and bromodomain 4, BRD4 IC50 5193 nM). The SAR we established is in good agreement with literature-reported CBP inhibitors, such as CBP30, and demonstrates the advantage of utilizing our two-step approach for inhibitor development of other bromodomains.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c02232?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02232</a>.Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02232/suppl_file/jm0c02232_si_001.csv">CSV</a>)BromoSCAN, differential scanning fluorometry (DSF), and cellular activity data of compounds 7, 16, and 23; crystallographic data collection and refinement statistics of compound 23; 1H NMR and 13C NMR of representative compounds; and HPLC traces of compounds 7, 16, and 23 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02232/suppl_file/jm0c02232_si_002.pdf">PDF</a>)Homology (docking) models of BRD4_5BT4_Cpd7 (UMB276) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02232/suppl_file/jm0c02232_si_003.pdb">PDB</a>)Homology (docking) models of BRD4_5BT4_Cpd-16 (UMB295) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02232/suppl_file/jm0c02232_si_004.pdb">PDB</a>)Homology (docking) models of BRD4_5BT4_Cpd-23 (UMB298) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02232/suppl_file/jm0c02232_si_005.pdb">PDB</a>)Homology (docking) models of CBP_4NR7_Cpd-3 (UMB274) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02232/suppl_file/jm0c02232_si_006.pdb">PDB</a>)Homology (docking) models of CBP_4NR7_Cpd-4 (UMB278) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02232/suppl_file/jm0c02232_si_007.pdb">PDB</a>)Homology (docking) models of CBP_4NR7_Cpd-7 (UMB276) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02232/suppl_file/jm0c02232_si_008.pdb">PDB</a>)Homology (docking) models of CBP_4NR7_Cpd-16 (UMB295) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02232/suppl_file/jm0c02232_si_009.pdb">PDB</a>)Homology (docking) models of CBP_4NR7_Cpd-23 (UMB298) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02232/suppl_file/jm0c02232_si_010.pdb">PDB</a>)Cocrystallographic data of compound 23 (UMB298) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02232/suppl_file/jm0c02232_si_011.pdb">PDB</a>)This article has not yet been cited by other publications.

Discovery and SAR Study of Boronic Acid-Based Selective PDE3B Inhibitors from a Novel DNA-Encoded Library

Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195)

Discovery of novel N-1 substituted pyrazolopyrimidinones as potent, selective PDE2 inhibitors

Discovery of BAY 2666605, a Molecular Glue for PDE3A and SLFN12

Discovery of Novel Purine Nucleoside Derivatives As Phosphodiesterase 2 (PDE2) Inhibitors: Structure-based Virtual Screening, Optimization and Biological Evaluation

Development of Dimethylisoxazole-Attached Imidazo[1,2- a ]pyridines as Potent and Selective CBP/P300 Inhibitors

Rational Design of 2-Chloroadenine Derivatives as Highly Selective Phosphodiesterase 8A Inhibitors

Discovery, Characterization, and Structure of a Cell Active PAD2 Inhibitor Acting through a Novel Allosteric Mechanism

Long-Timescale Simulations Revealed Critical Non-Conserved Residues of Phosphodiesterases Affecting Selectivity of BAY60-7550

Identification of selective inhibitors for phosphodiesterase 5A using e-pharmacophore modelling and large-scale virtual screening-based structure guided drug discovery approaches

Insights into the selective mechanism of PDE2/9a inhibitors from silico aspects

Therapeutic targeting of 3′,5′-cyclic nucleotide phosphodiesterases: inhibition and beyond

Discovery of effective phosphodiesterase 2 inhibitors with antioxidant activities for the treatment of Alzheimer's disease

Discovery, Characterization, and Optimization of a Novel Positive Allosteric Modulator-Antagonist of the D3 Dopamine Receptor

Discovery and optimization of a novel spiropyrrolidine inhibitor of β-secretase (BACE1) through fragment-based drug design.

Synthesis of 2,4-dihydroxyacetophenone derivatives as potent PDE-1 and -3 inhibitors: in vitro and in silico insights

Discovery of potent BET bromodomain 1 stereoselective inhibitors using DNA-encoded chemical library selections

Discovery of 2-(Anilino)pyrimidine-4-carboxamides as Highly Potent, Selective, and Orally Active Glycogen Synthase Kinase-3 (GSK-3) Inhibitors

Structure-based discovery of orally efficient inhibitors via unique interactions with H-pocket of PDE8 for the treatment of vascular dementia

Design, Synthesis and Biological Evaluation of Histone Deacetylase Inhibitors Based on Pyrrolo[2,3-d]pyrimidine and Pyrrolo[2,3-b]pyridine Scaffolds